1

- 3 Verena Haage¹, Edmilson Ferreira de Oliveira-Filho¹, Andres Moreira-Soto¹, Arne
- 4 Kühne¹, Carlo Fischer¹, Jilian Sacks³, Victor Max Corman^{1,2}, Marcel A. Müller^{1,2},
- 5 Christian Drosten^{1,2}, Jan Felix Drexler^{1,2*}
- ¹Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie
- 7 Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin,
- 8 Germany

11

14

15

17

18

19

20

21

- ⁹ ²German Centre for Infection Research (DZIF), Associated Partner Charité-
- 10 Universitätsmedizin Berlin, Berlin, Germany
- *Correspondence: Jan Felix Drexler, Helmut-Ruska-Haus, Institute of Virology, Campus
- 13 Charité Mitte, Charitéplatz 1, 10098 Berlin, Germany; Email: felix.drexler@charite.de

Key words: SARS-CoV-2, rapid antigen test, temperature stability, tropics, diagnostics

Abstract

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Rapid antigen-detecting tests (Aq-RDTs) can complement molecular diagnostics for COVID-19. The recommended temperature for storage of SARS-CoV-2 Ag-RDTs ranges between 5-30°C. In many countries that would benefit from SARS-CoV-2 Ag-RDTs, mean temperatures exceed 30°C. We assessed analytical sensitivity and specificity of eleven commercially available SARS-CoV-2 Aq-RDTs using different storage and operational temperatures, including (i) long-term storage and testing at recommended conditions, (ii) recommended storage conditions followed by 10 minutes exposure to 37°C and testing at 37°C and (iii) 3 weeks storage followed by testing at 37°C. The limits of detection of SARS-CoV-2 Ag-RDTs under recommended conditions ranged from 8.2x10⁵-7.9x10⁷ genome copies/ml of infectious SARS-CoV-2 cell culture supernatant. Despite long-term storage at recommended conditions, 10 minutes pre-incubation of Ag-RDTs and testing at 37°C resulted in about ten-fold reduced sensitivity for 46% of SARS-CoV-2 Aq-RDTs, including both Aq-RDTs currently listed for emergency use by the World Health Organization. After 3 weeks of storage at 37°C, 73% of SARS-CoV-2 Ag-RDTs exhibited about ten-fold reduced sensitivity. Specificity of SARS-CoV-2 Ag-RDTs using cell culture-derived human coronaviruses HCoV-229E and HCoV-OC43 was not affected by storage and testing at 37°C. In summary, short- and long-term exposure to elevated temperatures likely impairs sensitivity of several SARS-CoV-2 Ag-RDTs that may translate to false-negative test results at clinically relevant virus concentrations compatible with inter-individual transmission. Ensuring appropriate transport and storage conditions, and development of tests that are more robust across temperature fluctuations will be important for accurate use of SARS-CoV-2 Ag-RDTs in tropical settings.

Introduction

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

Advantages of SARS-CoV-2 antigen-detecting rapid diagnostic tests (Ag-RDTs) include fast results and their applicability on site without dependence on laboratory settings. Ag-RDTs are not intended to replace real-time RT-PCR as the gold standard for SARS-CoV-2 diagnostics (1, 2), but can be deployed for surveillance in high-risk environments or areas with insufficient laboratory capacity. With a constantly growing number of commercially available Ag-RDTs on the global market, the number of studies validating Aq-RDTs from different manufacturers is increasing rapidly (3-9). Those validation studies have so far not focused on the performance of Aq-RDTs under conditions that differ from recommended storage and test execution conditions (5-30°C), such as those observed in tropical settings where ambient temperatures commonly exceed 30°C (Figure 1A). This is challenging because tropical regions are strongly affected by the SARS-CoV-2 pandemic as evident from total cases reported from India, Brazil, Argentina, and Colombia, four out of the ten most affected countries worldwide by November 2020 (Figure 1B). Several studies have shown the need for validation of diagnostic tools in resource-limited tropical regions because co-endemic diseases can affect diagnostic test performance (10-14). The same might also apply to the environmental conditions under which Ag-RDTs are transported, stored and used. Temperature tolerance of SARS-CoV-2 diagnostic tools or environmental stability requirements have been previously discussed as hurdles and corresponding guidelines for stability testing of in vitro diagnostics are provided by the World Health Organization (WHO) (15, 16). To date, knowledge about temperature stability of SARS-CoV-2 Ag-RDTs is scarce.

To validate the performance of SARS-CoV-2 Ag-RDT in tropical settings, we compared

analytical sensitivity and specificity of eleven SARS-CoV-2 Ag-RDTs using recommended

and elevated temperatures.

Materials and Methods

Storage and testing of SARS-CoV-2 Ag-RDTs at 37°C

For storage at recommended conditions, the tests were stored at ambient temperature and were monitored that the room temperature stayed between 15-25°C. For storage at 37°C, SARS-CoV-2 Ag-RDTs were removed from cartons for space reasons and stored in plastic bags in a 37°C incubator for 19-21 days for sensitivity and 8-9 days for specificity testing. All tests were kept in their individual foil packaging until use. For experiments with infectious SARS-CoV-2, Ag-RDTs were transferred to a BSL-3 laboratory and stored in a 37°C incubator until test application. For specificity testing with infectious human coronavirus (HCoV)-229E and HCoV-OC43, SARS-CoV-2 Ag-RDTs were transferred to a BSL-2 laboratory and stored in a 37°C incubator until test validation. For experiments testing short-term exposure to 37°C following storage at recommended temperatures, SARS-CoV-2 Ag-RDTs were transferred to a BSL-3 laboratory and stored for 10 minutes in a 37°C incubator until test operation. After application of SARS-CoV-2, HCoV-229E or HCoV-OC43 cell culture supernatant in a biological safety cabinet, Ag-RDTs were further incubated in a 37°C incubator until readout of the results.

Analytical sensitivity

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

SARS-CoV-2 (BetaCoV/Munich/ChVir984/2020) was grown on Vero E6 cells (C1008: African green monkey kidney cells) and maintained in DMEM containing 10% FCS at 37°C with 5% CO2. Viral RNA was extracted from cell culture supernatant using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA concentration was determined by specific real-time RT-PCR and in vitro-transcribed RNA standards designed for absolute quantification of virus concentrations (17, 18). For determination of the limit of detection (LOD), a SARS-CoV-2 stock (3.1x10⁹ copies/ml) was serially diluted in plain DMEM and 5µl/dilution were added to the extraction buffer of the respective kit for validation experiments. For the Coris COVID-19 Ag Respi-Strip test, 5µl of SARS-CoV-2 supernatant was added to 95µl of PBS to reach the required sample volume of 100µl prior to addition of LY-S buffer to the sample for test validation. Initially, validation experiments were performed in triplicates for a small subset of tests (ActivXpress, Genedia, ichroma, JOYSBIO) at recommended conditions (i) with all three replicates showing the same result (Supplementary Table 1). Consequently, validation experiments for all included tests were subsequently performed in duplicates due to a limited amount of available tests for all conditions tested. LOD was defined as the lowest dilution at which both replicates were positive. A dilution factor correction was applied based on the volume of extraction buffer (range between kits, 100-500µl) provided by each SARS-CoV-2 Ag-RDT kit.

Analytical specificity

Specificity was tested using cell culture supernatant of HCoV-229E and HCoV-OC43, grown on CaCo-2 cells. Quantification of viral stocks was performed by RT-PCR using an in house protocol and photometrically quantified *in vitro*-transcribed RNA standards as described above. 5µl of stocks were directly used for validation experiments. The required sample volume of 100µl for the Coris COVID-19 Ag Respi-Strip was reached as described above. Experiments were performed in duplicates.

Interpretation of test results

Tests were performed according to the test-specific supplier instructions for use, except for the sample preparation as noted above. Results in the form of a band on immunochromatography paper were scored independently by two persons except for the reader-based tests Bioeasy 2019-nCoV Ag and ichroma - COVID-19 Ag. In case of discrepancy for visual tests, a third person was consulted to reach a final decision. Results were defined as unclear when a weak, discontinuous band or smear was observed that could not be clearly defined as a positive or negative result. In case of test failure indicated by absence of a visible positive control band, the test procedure was repeated with the same sample.

World heat map

Data of maximum temperatures of the hottest month (°C) on country level at the spatial resolution of 2.5 min were obtained from WorldClim 2 (19). National means were

Results

At present, there are at least 119 SARS-CoV-2 Ag-RDTs commercially available (21). Eleven of those SARS-CoV-2 rapid antigen tests were selected for temperature stability validation based on the availability of clinical performance data (3), and manufacturing by leading suppliers implying availability on the global market (**Table 1**). Subsequently, analytical performance of selected SARS-CoV-2 Ag-RDTs was assessed following storage and application of tests under recommended conditions as well as elevated temperatures (termed tropical conditions henceforth), using three different experimental settings.

Table 1. Overview of SARS-CoV-2 rapid antigen tests included in the study

ID	Test	Manufacturer	Readout	Lot No.
I	Panbio™ COVID-19 Ag	Abbott Laboratories	Visual	41ADF012A
	Rapid Test			
II	ActivXpress + COVID-19	Edinburgh Genetics	Visual	AG20200905
	Antigen Complete Testing			
	Kit			
III	Bioeasy 2019-nCoV Ag	Shenzhen Bioeasy	Reader	2003N406
	Fluorescence Rapid Test Kit	Biotechnology Co.,		
		Ltd		
IV	Clinitest Rapid COVID-19	Siemens	Visual	2010184
	Antigen Test	Healthineers		

V	Covid.19 Ag Respi-Strip	Coris BioConcept	Visual	43871J2008
				4376012015
VI	COVID-19 Ag	Genedia	Visual	643X2005
VII	ichroma - COVID-19 Ag	Boditech Med	Reader	SRQHA27
VIII	COVID-19 Antigen Rapid	JOYSBIO (Tianjin)	Visual	2020092409
	Test Kit	Biotechnology Co.,		
		Ltd.		
IX	NowCheck COVID-19 Ag	BIONOTE INC.	Visual	1901D002 Code GEN
	test			
X	SARS-CoV-2 Rapid Antigen	Roche Diagnostics	Visual	QCO3020083
	Test			QCO390003I/Sub:I-2
				QCO390011A/Sub:A-
				2
XI	STANDARD Q COVID-19	SD Biosensor, Inc.	Visual	QCO3020040A
	Test			

The first setting was (i) storage at recommended conditions (room temperature (rt); 15-30°C) for 1-6 months and test incubation at recommended conditions (rt; 15-30°C). The second setting was (ii) storage at recommended conditions (rt; 15-30°C) for 1-6 months, 10 minutes pre-incubation of tests at 37°C prior to testing and test incubation at 37°C so as to mimic recommended storage of kits prior to test usage under non air-conditioned conditions in tropical settings. The third setting was (iii) storage under tropical conditions (37°C) for 19-21 days followed by test incubation at 37°C to mimic non air-conditioned storage and test application in tropical settings (**Figure 2**).

First, we determined analytical sensitivity at recommended conditions by determining the limit of detection (LOD) of SARS-CoV-2 Ag-RDTs at room temperature using serial

dilutions of SARS-CoV-2 cell culture supernatant (dilution range: 7.2x10⁶ copies/ml to 3.1x10⁹ copies/ml; **Table 2**) following storage for 1-6 months at room temperature. Prior to performing all experiments in duplicates we validated analytical sensitivity for a small subset of tests at recommended conditions in triplicates, showing that results for duplicates and triplicates were identical (**Supplementary Table 1**). As extraction buffer volumes differ between manufacturers and a constant volume of SARS-CoV-2 supernatant was applied for validation experiments, the limit of detection (LOD) for each Ag-RDT was calculated by correcting for the respective dilution factor. The dilution-factor corrected limit of detection (LOD) for validated SARS-CoV-2 Ag-RDTs ranged from 8.2x10⁵ copies/ml to 7.9x10⁷ copies/ml of SARS-CoV-2 cell culture supernatant (**Table 2**). Those LODs were consistent with previously published virus concentrations for validation of Ag-RDTs using clinical samples (3), suggesting robustness of our data. Our data also highlight profound differences in analytical sensitivity of up to 100-fold for SARS-CoV-2 Ag-RDTs from different manufacturers.

Table 2. Analytical Sensitivity of SARS-CoV-2 rapid antigen tests at recommended storage and test conditions

SARS-CoV-2 (copies/ml)	I	II	III	IV	V	VI	VII	VIII	IX	Х	ΧI
3.1x10 ⁹	++	++	++	++	++	++	++	++	++	++	++
7.0x10 ⁸	++	++	++	++	?	?	++	++	++	++	++
7.0x10 ⁷	++	++	-	+	-	-	++	+	++	+	++
7.2x10 ⁶	-	-	-	-	-	-	-	-	-	-	-
Corrected SARS-CoV- 2 LOD (copies/ml)	1.2x10 ⁶	1.4x10 ⁶	7.0x10 ⁶	1.1x10 ⁶	7.9x10 ⁷	4.6x10 ⁷	8.2x10 ⁵	1.4x10 ⁶	1.0x10 ⁶	1.0x10 ⁶	1.0x10 ⁶

I: Abbott; II ActivXpress; III Bioeasy; IV Clinitest; V Coris; VI Genedia; VII ichroma; VIII

We then assessed analytical sensitivity of SARS-CoV-2 Ag-RDTs following short- and long-term exposure to 37°C (settings (ii) and (iii); **Figure 2**) by determining the level of detection (LOD) using identical serial dilutions of SARS-CoV-2 cell culture supernatant. The analytical sensitivity of about half of the evaluated SARS-CoV-2 Ag-RDTs (five out of eleven; 46%) was already compromised by about ten-fold when tests were stored under recommended conditions but exposed to 37°C for only ten minutes prior to testing at 37°C (**Figure 3**). After 19-21 days storage at 37°C and testing at 37°C, eight out of the eleven SARS-CoV-2 Ag-RDTs (73%) showed an about ten-fold reduction in analytical sensitivity when compared to recommended temperatures.

JOYSBIO; IX NowCheck; X Roche; XI Standard Q. ++ positive; + weak positive; -

negative; ? unclear result. LOD: limit of detection.

Additionally, analytical specificity of SARS-CoV-2 Ag-RDTs under recommended and under tropical storage and test application conditions ((i) and (iii); **Figure 2**) was examined by testing for cross-reactivity with the ubiquitous HCoV-229E (2.9x10⁷ copies/ml) and HCoV-OC43 (1.0x10⁶ copies/ml) (22, 23). Those HCoV concentrations were selected according to the guidelines on analytical specificity testing for SARS-CoV-2 Ag-RDTs published by the German Federal institute for vaccines and biomedicines (24). SARS-CoV-2 Ag-RDTs showed no cross-reactivity with HCoV-229E or HCoV-OC43 upon storage and testing at elevated temperatures (**Table 3**).

Table 3. Analytical Specificity of SARS-CoV-2 rapid antigen tests at recommended and tropical storage and test application conditions

Condition	Virus	Cps/ml	ı	II	III	IV	V	VI	VII	VIII	IX	X	ΧI
(i)	HCoV- 229E	2.9x10 ⁷	-	-	-	-	-	-	-	-	-	-	-
(iii)			-	-	-	-	-	-	-	-	-	-	-
(i)	HCoV-	1.0x10 ⁶	-	-	-	-	-	-	-	-	-	-	-
(iii)	OC43	•	-	-	-	-	-	-	-	-	-	-	-

I: Abbott; II ActivXpress; III Bioeasy; IV Clinitest; V Coris; VI Genedia; VII ichroma; VIII JOYSBIO; IX NowCheck; X Roche; XI Standard Q.+ positive; - negative. Cps, Genome copies.

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

Our study highlights that even short-term exposure to elevated temperatures may compromise sensitivity of currently available SARS-CoV-2 Ag-RDTs. Our data are consistent with impaired sensitivity of other Ag-RDTs at elevated temperatures, including Malaria rapid diagnostic tests (MRDTs). An assessment of five MRDTs reported a 13% to 53% decline in sensitivity for three MRDTs following 90 days of storage at 35°C (25). Moreover, an evaluation assessing temperature stability of dengue NS1 antigen-based RDTs at 35°C showed a gradual decline in test sensitivity for seven out of eight tested dengue Aq-RTDs after storage for about 20 days at elevated temperatures (26). Beyond storage, elevated temperatures during shipment can also affect Ag-RDT performance. Supply chains of MRDTs were studied in Burkina Faso, Senegal, Ethiopia, the Philippines and Cambodia, demonstrating regular exceeding of 30°C during transport (27, 28). Consequently, the WHO recommends heat stability testing between 35°C and 40°C for MRDTs (29) and supply and delivery chains to tropical countries must contain adequate cold chains (30). As discussed by others, temperature stability guidelines for in vitro diagnostics exist, however there are currently no specific guidelines for the validation of Ag-RDTs regarding temperature stability (31-34). Common validation guidelines including environmental conditions could be a first step towards globally reliable diagnostics. At the same time, our data imply a huge challenge to tropical countries with regard to adequate storage of SARS-CoV-2 Ag-RDTs. Besides storage capacity, temperature control and monitoring of storage facilities is required, especially for long-term storage of

Ag-RDTs. To guarantee temperature-regulated storage, a certain level of infrastructure is

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

13

exposure to elevated temperatures may compromise sensitivity of SARS-CoV-2 Ag-RDTs

Funding

This study is based on research funded in part by the Bill & Melinda Gates Foundation (grant ID INV-005971). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The study was further supported in part by the Foundation for Innovative New Diagnostics (FIND), including procurement of some test kits.

Conflicts of Interest: The authors declare no conflict of interest.

Author Contributions: V.H.: conceptualization, investigation, validation, formal analysis, data curation, writing – original draft preparation, visualization. E.F.: methodology, investigation, validation. A.M.S.: investigation, validation, visualization. A.K.: investigation. C.F.: visualization, software. J.S.: methodology, resources, writing. V.M.C.: methodology. C.D.: methodology. J.F.D.: conceptualization, methodology, resources, writing – original draft preparation, visualization, supervision, project administration, funding acquisition. All authors have read and agreed to the published version of the manuscript.

- Jayamohan H, Lambert CJ, Sant HJ, Jafek A, Patel D, Feng H, Beeman M, Mahmood T,
 Nze U, Gale BK. 2020. SARS-CoV-2 pandemic: a review of molecular diagnostic tools
 including sample collection and commercial response with associated advantages and
 limitations. Analytical and Bioanalytical Chemistry doi:10.1007/s00216-020-02958-1.
- 288 2. European Centre for Disease Prevention and Control S. 2020. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. Technical Report.
- Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, Jó Lei
 WK, Tscheak P, Möncke-Buchner E, Müller MA, Krumbholz A, Drexler JF, Drosten C.
 2020. Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests.
 medRxiv doi:10.1101/2020.11.12.20230292:2020.11.12.20230292.
- Iglòi Z, Velzing J, van Beek J, van de Vijver D, Aron G, Ensing R, Benschop K, Han W,
 Boelsums T, Koopmans M, Geurtsvankessel C, Molenkamp R. 2020. Clinical evaluation of the Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a municipal health service drive-through testing site. medRxiv doi:10.1101/2020.11.18.20234104.
- Krüger LJ, Gaeddert M, Köppel L, Brümmer LE, Gottschalk C, Miranda IB, Schnitzler P,
 Kräusslich HG, Lindner AK, Nikolai O, Mockenhaupt FP, Seybold J, Corman VM,
 Drosten C, Pollock NR, Cubas-Atienzar AI, Kontogianni K, Collins A, Wright AH, Knorr B,
 Welker A, de Vos M, Sacks JA, Adams ER, Denkinger CM. 2020. Evaluation of the
 accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of care diagnostics for SARS-CoV-2. medRxiv
 doi:10.1101/2020.10.01.20203836:2020.10.01.20203836.
- Lindner AK, Nikolai O, Rohardt C, Burock S, Hülso C, Bölke A, Gertler M, Krüger LJ, Gaeddert M, Tobian F, Lainati F, Seybold J, Jones TC, Hofmann J, Sacks JA, Mockenhaupt FP, Denkinger CM. 2020. Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected anterior nasal versus nasopharyngeal swab. medRxiv doi:10.1101/2020.12.03.20243725:2020.12.03.20243725.
- Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque Afonso AM, Le Goff J, Delaugerre C. 2020. Evaluation of a Rapid Diagnostic Assay for
 Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. J Clin Microbiol 58.
- Mertens P, De Vos N, Martiny D, Jassoy C, Mirazimi A, Cuypers L, Van den Wijngaert S, Monteil V, Melin P, Stoffels K, Yin N, Mileto D, Delaunoy S, Magein H, Lagrou K, Bouzet J, Serrano G, Wautier M, Leclipteux T, Van Ranst M, Vandenberg O, L-US-C-WDG, Gulbis B, Brancart F, Bry F, Cantinieaux B, Corazza F, Cotton F, Dresselhuis M, Mahadeb B, Roels O, Vanderlinden J. 2020. Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Frontiers in Medicine 7.
- Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, Chan RC, Tsang DN. 2020.
 Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. J Clin Virol
 129:104500.
- Yadouleton A, Sander AL, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, Fischer
 C, Krause N, Akogbeto P, de Oliveira Filho EF, Dossou A, Brünink S, Aïssi MAJ,
 Djingarey MH, Hounkpatin B, Nagel M, Drexler JF. 2021. Limited Specificity of Serologic
 Tests for SARS-CoV-2 Antibody Detection, Benin. Emerg Infect Dis 27.
- 11. Nath H, Mallick A, Roy S, Sukla S, Basu K, De A, Biswas S. 2020. Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-positive results for both viruses in regions where both COVID-19 and Dengue co-exist. medRxiv doi:10.1101/2020.07.03.20145797:2020.07.03.20145797.

- Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, Gerlic M, Munitz A, Doolman R, Asraf K, Shlush LI, Vivante A. 2020. Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America doi:10.1093/cid/ciaa1207.
- Ombelet S, Ronat JB, Walsh T, Yansouni CP, Cox J, Vlieghe E, Martiny D, Semret M, Vandenberg O, Jacobs J. 2018. Clinical bacteriology in low-resource settings: today's solutions. Lancet Infect Dis 18:e248-e258.
- 340 14. Fischer C, Drosten C, Drexler JF. 2019. The difficulties in obtaining reliable Zika virus diagnostics. Lancet Infect Dis 19:240-241.
- Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. 2020. Considerations
 for diagnostic COVID-19 tests. Nature Reviews Microbiology doi:10.1038/s41579-020-00461-z.
- Organization WH. 2017. Technical guidance series (TGS) for WHO prequalification –
 diagnostic assessment panels for quality assurance and quality control of in vitro
 diagnostic medical devices. Technical Guidance vol. 6.
- Drexler JF, Kupfer B, Petersen N, Grotto RM, Rodrigues SM, Grywna K, Panning M,
 Annan A, Silva GF, Douglas J, Koay ES, Smuts H, Netto EM, Simmonds P, Pardini MI,
 Roth WK, Drosten C. 2009. A novel diagnostic target in the hepatitis C virus genome.
 PLoS Med 6:e31.
- Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S,
 Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S,
 Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken
 C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV)
 by real-time RT-PCR. Euro Surveill 25.
- 357 19. http://www.worldclim.com/version2. Accessed 25.11.2020.
- 358 20. https://www.worldometers.info/coronavirus/#countries. Accessed 25.11.2020.
- 359 21. https://www.finddx.org/covid-19/pipeline. Accessed 23.12.2020.
- Annan A, Ebach F, Corman VM, Krumkamp R, Adu-Sarkodie Y, Eis-Hübinger AM, Kruppa T, Simon A, May J, Evans J, Panning M, Drosten C, Drexler JF. 2016. Similar virus spectra and seasonality in paediatric patients with acute respiratory disease, Ghana and Germany. Clin Microbiol Infect 22:340-346.
- 364 23. Góes LGB, Zerbinati RM, Tateno AF, de Souza AV, Ebach F, Corman VM, Moreira-Filho
 365 CA, Durigon EL, da Silva Filho L, Drexler JF. 2020. Typical epidemiology of respiratory
 366 virus infections in a Brazilian slum. J Med Virol 92:1316-1321.
- Arzneimittel Bflub. 2020. Mindestkriterien für SARS-CoV-2 Antigentests im Sinne
 von § 1 Abs. 1 Satz 1 TestVO: Antigenschnelltests.
- Chiodini PL, Bowers K, Jorgensen P, Barnwell JW, Grady KK, Luchavez J, Moody AH, Cenizal A, Bell D. 2007. The heat stability of Plasmodium lactate dehydrogenase-based and histidine-rich protein 2-based malaria rapid diagnostic tests. Trans R Soc Trop Med Hyg 101:331-7.
- Blacksell SD, Newton PN, Bell D, Kelley J, Mammen MP, Jr., Vaughn DW, Wuthiekanun
 V, Sungkakum A, Nisalak A, Day NPJ. 2006. The Comparative Accuracy of 8
 Commercial Rapid Immunochromatographic Assays for the Diagnosis of Acute Dengue
 Virus Infection. Clinical Infectious Diseases 42:1127-1134.
- Albertini A, Lee E, Coulibaly SO, Sleshi M, Faye B, Mationg ML, Ouedraogo K, Tsadik
 AG, Feleke SM, Diallo I, Gaye O, Luchavez J, Bennett J, Bell D. 2012. Malaria rapid
 diagnostic test transport and storage conditions in Burkina Faso, Senegal, Ethiopia and
 the Philippines. Malar J 11:406.
- Jorgensen P, Chanthap L, Rebueno A, Tsuyuoka R, Bell D. 2006. Malaria rapid diagnostic tests in tropical climates: the need for a cool chain. Am J Trop Med Hyg 74:750-4.

- World Health Organization FfIND, Center for Disease Control and Prevention. 2014.
 Malaria rapid diagnostic test performance. Results of WHO product testing of malaria RDTs, Round 5 2014.
- 30. Organization WH. 2004. The Use of Malaria Rapid Diagnostic Tests. Manila: World Health Organization.
- 31. Phommasone K, Sengvilaipaseuth O, de Lamballerie X, Vongsouvath M, Phonemixay O, Blacksell SD, Newton PN, Dubot-Pérès A. 2015. Temperature and the field stability of a dengue rapid diagnostic test in the tropics. Am J Trop Med Hyg 93:33-39.
- 392 32. Wayne P. 2009. Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guidelines. Clinical and Laboratory Standards Institute EP25-A.
- 394 33. Defense USDo. 2008. Environmental Engineering Considerations and Laboratory Tests. MIL-STD-810G.
- 34. Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, Poole F, Smith PG, Sriram N,
 Wongsrichanalai C, Linke R, O'Brien R, Perkins M, Cunningham J, Matsoso P,
 Nathanson CM, Olliaro P, Peeling RW, Ramsay A. 2006. Evaluation of diagnostic tests
 for infectious diseases: general principles. Nat Rev Microbiol 4:S21-31.
- Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D,
 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J,
 Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. 2020. Virological assessment of
 hospitalized patients with COVID-2019. Nature 581:465-469.

409

410

411

412

413

414

415

416

417

418

419

420

421

404 36. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe doi:10.1016/S2666-407 5247(20)30172-5.




Figure 1. COVID-19 case numbers and mean temperatures globally. A. World map representing global temperature distribution based on maximum temperature of the warmest month (°C) freely available from WorldClim 2 (19). B. Graph represents total COVID-19 cases in the ten most affected countries globally by 25th of November 2020 (20).




Figure 2. Experimental setup for validation of SARS-CoV-2 Ag-RDTs. (i): storage and operation at recommended conditions; (ii): recommended storage and operation at tropical conditions; (iii): storage and operation at tropical conditions.



Figure 3. Sensitivity of SARS-CoV-2 Aq-RDTs decreases at elevated temperatures.

Analytical sensitivity of SARS-CoV-2 rapid antigen tests upon different storage and operation conditions; (i): rt storage- rt testing, blue; (ii): rt storage - 37°C 10 min pre-incubation - 37°C testing, yellow; (iii): 37°C storage - 37°C testing, orange. ++ positive; + weak positive; - negative; ? unclear result. 1/2, 2/2: number of replicates. LOD: limit of detection. rt: room temperature.

478 recommended storage and test conditions

Test	Ad	ActivXpress			Genedia			chrom	а	JOYSBIO		
Replicate	1	2	3	1	2	3	1	2	3	1	2	3
SARS-CoV-2 (copies/ml)												
3.1x10 ⁹	++	++	++	++	++	++	++	++	++	++	++	++
7.0x10 ⁸	++	++	++	?	?	?	++	++	++	++	++	++
7.0x10 ⁷	++	++	++	-	-	-	++	++	++	+	+	+
7.2x10 ⁶	-	-	-	-	-	-	-	-	-	-	-	-

⁺⁺ positive; + weak positive; - negative; ? unclear result. LOD: limit of detection.